Metavia Inc (MTVA) Stock Price, Quote & News

Company Profile

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomod...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 702 9600

Website: www.metaviatx.com

Address:

545 Concord Avenue, Suite 210, Cambridge, United States

Kertzi Feb. 4 at 5:02 AM

$MTVA World-class business model 🤡 SEC Form 8-K (Jan 23, 2026): MetaVia has 2 (two!) registered employees... CEO: $756,328 CFO: $562,985 ➡️ $1,319,313 paid to two people in 2025 $0 revenue $0 profitability Stock < $2 Endless dilution Shareholders wiped Shareholders fund the company. Executives cash the checks. SEC filings don’t lie.

0 · Reply

GemstoneTrades Feb. 3 at 6:21 PM

The broad market downturn is masking MetaVia’s ($MTVA) strong technical setup. While the stock may be down in "sympathy" with the Nasdaq, the internal mechanics are heavily skewed toward a recovery. The "Coiled Spring" Summary The Cash Moat: MetaVia is not a "zombie." With $18.9M in estimated cash post-January offering, they have the runway to reach critical clinical milestones regardless of temporary market red days. The Data Edge: Market cycles don't change the science. Their 9.1% weight loss in 8 weeks remains competitive with industry giants, supporting analyst targets as high as $48.00–$91.00. Short Trap: Short interest has spiked 729%, while borrow fees remain exorbitant at ~328%. Failed Deliveries: Significant Fails-to-Deliver (FTDs) from December and January must eventually be settled. The Bottom Line: You are holding a company trading for less than its cash value. The current drop is a reflection of the market's mood, not the drug's value.

2 · Reply

BigBoyTroy Feb. 3 at 5:29 PM

$MTVA I take some of this for a swing down here showed up in my criteria it will move in 3 to 20 days or sooner time stamped today

0 · Reply

TraderRapp Feb. 3 at 4:13 PM

$MTVA train wreck...bodies everywhere...

1 · Reply

Kertzi Feb. 3 at 3:28 PM

$MTVA It will go back under a dollar in a month! There are 10 Million more shares waiting to be printed and sold to retail investors. Korean SCAM. Less than 10 employees... Fake Pharma! Korean Ding Dong-ST can pull of the plug at any time.

1 · Reply

GemstoneTrades Feb. 3 at 11:30 AM

$MTVA remains quiet, likely a tactical move to maximize the impact of their next catalyst. Management understands that dropping news into a volatile market wastes the leverage provided by their 2.3 million share float. By waiting for a "green" market day, they ensure the highest probability of a short squeeze toward $10.00. Strategic Delay & Incentives: The silence aligns with recent LinkedIn activity showing a pivot toward Clinical Operations. Management is likely waiting to announce "First Patient Dosed" for the 16-week titration study—a massive "de-risking" event. With top executives holding 60,000 RSUs, they are personally incentivized to push the stock past the $4.65 call trigger to unlock $28M in warrant cash. Market Outlook: Trading at a distressed $8M valuation, any positive clinical update could trigger an explosive "gap fill" toward $5.40. Analysts maintain targets up to $91.00, reflecting a standard biotech rerate.

1 · Reply

Caveman25 Feb. 3 at 7:24 AM

$MTVA As of February 3, 2026, MetaVia ($MTVA) remains quiet, likely a tactical move to maximize the impact of their next catalyst. Management understands that dropping news into a volatile market wastes the leverage provided by their 2.3 million share float. By waiting for a "green" market day, they ensure the highest probability of a short squeeze toward $10.00. Strategic Delay & Incentives: The silence aligns with recent LinkedIn activity showing a pivot toward Clinical Operations. Management is likely waiting to announce "First Patient Dosed" for the 16-week titration study—a massive "de-risking" event. With top executives holding 60,000 RSUs, they are personally incentivized to push the stock past the $4.65 call trigger to unlock $28M in warrant cash. Market Outlook: Trading at a distressed $8M valuation, any positive clinical update could trigger an explosive "gap fill" toward $5.40. Analysts maintain targets up to $91.00, reflecting a standard biotech rerate.

0 · Reply

MGAP Feb. 2 at 10:12 PM

$MTVA what happened ?

1 · Reply

Orlandotrader Feb. 2 at 9:06 PM

$MTVA You can keep playing Fuck Fuck but eventually this will Rock much Higher.

2 · Reply

Armazi_Capital Feb. 2 at 6:30 PM

$MTVA im in :)

2 · Reply

MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option

Jan 15, 2026, 9:32 AM EST - 19 days ago

MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering

Jan 5, 2026, 8:30 AM EST - 4 weeks ago

MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile

Dec 29, 2025, 8:31 AM EST - 5 weeks ago

MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference

Dec 22, 2025, 8:31 AM EST - 6 weeks ago

MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement

Dec 2, 2025, 8:45 AM EST - 2 months ago

MetaVia Inc. Announces 1-for-11 Reverse Stock Split

Nov 7, 2025, 8:31 AM EST - 3 months ago

MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025

Nov 6, 2025, 8:31 AM EST - 3 months ago

MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 4, 2025, 4:01 PM EST - 3 months ago

MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025

Oct 27, 2025, 8:31 AM EDT - 3 months ago

MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting

Oct 20, 2025, 8:31 AM EDT - 3 months ago

MetaVia Announces Poster Presentations on DA-1726 at ObesityWeek® 2025

Oct 14, 2025, 8:31 AM EDT - 4 months ago

MetaVia to Present at the H.C. Wainwright Liver Disease Virtual Conference

Aug 26, 2025, 8:31 AM EDT - 5 months ago

MetaVia to Present at Upcoming Investor and Industry Conferences

Aug 7, 2025, 8:31 AM EDT - 6 months ago

MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 8:31 AM EDT - 6 months ago

MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient

Aug 4, 2025, 8:31 AM EDT - 6 months ago

MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241

Jul 9, 2025, 8:31 AM EDT - 7 months ago

MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose

Jun 21, 2025, 9:00 AM EDT - 8 months ago

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session

Jun 10, 2025, 8:31 AM EDT - 8 months ago

MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th

Jun 4, 2025, 8:31 AM EDT - 8 months ago

MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions

May 14, 2025, 4:05 PM EDT - 9 months ago

MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 9, 2025, 8:01 AM EDT - 9 months ago

MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

May 7, 2025, 2:00 AM EDT - 9 months ago

MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025

Apr 23, 2025, 8:31 AM EDT - 10 months ago

MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025

Apr 22, 2025, 8:31 AM EDT - 10 months ago

MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential

Apr 15, 2025, 7:01 AM EDT - 10 months ago

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability

Mar 20, 2025, 7:31 AM EDT - 11 months ago

MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update

Jan 10, 2025, 8:05 AM EST - 1 year ago

MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference

Nov 18, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

Nov 13, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

Nov 7, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 4, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Oct 1, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals to Participate in Investor Conferences in October

Sep 30, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Sep 3, 2024, 8:01 AM EDT - 1 year ago

NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Aug 6, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity

Jul 30, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01

Jul 11, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July

Jun 26, 2024, 9:06 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Jun 25, 2024, 5:08 PM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 24, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 22, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models

May 22, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone

May 9, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 30, 2024, 8:01 AM EDT - 1 year ago

NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June

Apr 17, 2024, 8:05 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Apr 1, 2024, 8:01 AM EDT - 2 years ago

NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Mar 28, 2024, 8:01 AM EDT - 2 years ago

NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

Kertzi Feb. 4 at 5:02 AM

0 · Reply

GemstoneTrades Feb. 3 at 6:21 PM

2 · Reply

BigBoyTroy Feb. 3 at 5:29 PM

$MTVA I take some of this for a swing down here showed up in my criteria it will move in 3 to 20 days or sooner time stamped today

0 · Reply

TraderRapp Feb. 3 at 4:13 PM

$MTVA train wreck...bodies everywhere...

1 · Reply

Kertzi Feb. 3 at 3:28 PM

1 · Reply

GemstoneTrades Feb. 3 at 11:30 AM

1 · Reply

Caveman25 Feb. 3 at 7:24 AM

0 · Reply

MGAP Feb. 2 at 10:12 PM

$MTVA what happened ?

1 · Reply

Orlandotrader Feb. 2 at 9:06 PM

$MTVA You can keep playing Fuck Fuck but eventually this will Rock much Higher.

2 · Reply

Armazi_Capital Feb. 2 at 6:30 PM

$MTVA im in :)

2 · Reply

MadMaverick Feb. 2 at 5:34 PM

🚨 $MTVA: The Next Frontier in the Obesity & GLP-1 Market 🔹 High-Growth Play: Direct exposure to the multi-billion dollar obesity and metabolic health sector. 🔹 Clinical Catalyst: Advancing DA-1726, a dual-agonist drug with best-in-class potential for weight loss. 🔹 Fully Funded: Recently secured $9.3M in capital to drive upcoming clinical milestones. 🔹 Pure Proxy: A high-upside public-market vehicle for the next wave of biotech breakthroughs. Why $MTVA stands out: 🔸 Targets both Obesity and MASH—two of the largest unmet needs in modern medicine. 🔸 Strong Phase 1b data showing significant weight loss results and a clean safety profile. 🔸 Positioned for momentum as the global demand for GLP-1 treatments skyrockets. MTVA looks rough so far in 2026 with price and sentiment tanking. However, despite the sell-off, volume is starting to surge, showing some life under the surface. Communicated Disclaimer - https://chartingdaily.com/metabolic-health $NVO $LLY $BMY $JNJ

1 · Reply

Jw242 Feb. 2 at 5:08 PM

$MTVA that was it? Time to sell I guess

1 · Reply

DayTrade_4Life Feb. 1 at 9:58 PM

Watchlist for 2 to 6 Feb. See Profile for more info. VHUB: Spt $10; Breakout $20 CISS: Spt 1.90; Breakout 2.80 / $3 DKI: Spt .68; Breakout 1.20 then 1.75 YJ: Spt; 1.75; Breakout $3 XTKG: Spt .28; Breakout .42 $ANL: Breakout $13 $SGN: Breakout .35 $MTVA: Spt 2.55; Breakout 2.70 $GLSI: Spt $28; Breakout $37 $GUTS: Breakout .50 ELPW: Breakout 6.30 ASBP: Breakout 2.45 YCBD: Support $1; Breakout 1.30 BURU: Support .19; Breakout .21

0 · Reply

DayTrade_4Life Jan. 31 at 6:51 PM

👀Some Stocks to Watch for Monday 2 Feb: VHUB DKI XTKG CISS YJ $GUTS $ELPW $MTVA 🏆Alerts since last Week in image below. 🔥See Profile and Posts for more info. 💰Live Alerts, Watchlists, Swing Plays, Amazing Scanners & News Suite, Trading Education, Guidance. 👀Join me on X. Link in Profile.

0 · Reply

echo_fable Jan. 31 at 1:38 AM

$MTVA good close today

1 · Reply

GemstoneTrades Jan. 31 at 12:57 AM

$MTVA

0 · Reply

GemstoneTrades Jan. 31 at 12:29 AM

As of January 31, 2026, MetaVia ($MTVA) is a clinical-stage "dark horse" in the obesity sector. Choosing a 1-for-11 reverse split instead of an aggressive 1-for-50 was a calculated move to preserve institutional liquidity and stay within Nasdaq’s "safe zone." This decision leaves a tradeable float of 2.3 million shares, perfect for a sustained squeeze. Management Incentives: Management is operationally locked-in. In late January 2026, the CEO and CFO were granted 60,000 RSUs and cash bonuses, anchoring their wealth to a recovery. Their goal is driving the stock past $4.65 to "call" Series D warrants, which would refill the treasury with $28 million without further diluting the float. Market Cap Potential: Currently valued at a distressed 8 million USD, MetaVia trades at a fraction of its peers. A re-rating to a modest $180 million market cap—standard for Phase 2 obesity firms—would imply a stock price of $60.00.

0 · Reply

GemstoneTrades Jan. 30 at 10:47 PM

$MTVA As of January 31, 2026, MetaVia ($MTVA) is a high-stakes clinical play trading near a $8M market cap—an extreme valuation gap for a firm with positive Phase 1b results. Following a 1-for-11 reverse split and a $9.3M offering priced at $3.10, management is now under immense pressure to recover shareholder value. Executive Incentives: Management is heavily "locked-in." Recent RSU grants and cash bonuses align the C-suite with a recovery. Their primary target is driving the stock past $3.10 to unlock $28M in warrant proceeds, securing the company’s survival through 2027. Market Cap Potential: If Monday brings a "Roadmap PR" detailing the 16-week titration study, the stock could quickly fill the technical gap toward $5.40. A rerate to a modest $180M market cap (common for Phase 2 obesity biotechs) would imply a stock price near $60.00. Despite dilution risks, the backing of majority-owner Dong-A ST provides a strategic floor for this "dark horse" contender.

1 · Reply

Kertzi Jan. 30 at 6:22 AM

$MTVA -77% -$15,000 in one month! This is the worst investment ever! Screw you, Korean scammers!

1 · Reply

starbucks_cups_with_rum Jan. 29 at 8:28 PM

$MTVA this is the last time I buy stocks drunk

1 · Reply

TradeSun Jan. 29 at 7:10 PM

$GUTS As of PR from January -> $ 85M cash on hand, (end of q3 $ 77M) so cash runway for one more year. MCap $ 90M now. Traded on cash now. Usually a good sign for a bounce, imo. But pretty hard to raise cash at this SP level. Hope for you guys to see a fat bounce here!!! $MTVA $ALT $GLMD $BIOBI*ch

1 · Reply

DanishViking92 Jan. 28 at 9:31 PM

$BCTX this wasnt that bad - if you take a look at $SLS and $MTVA this is half the drop they suffered today. Future is looking brighter than ever! (SLS is going to skyrocket once they hit 80th event - same with BCTX once they announce phase 3 data!) The difference is that BCTX just bottomed out and are on early run-up to data - big buying opportunity!

3 · Reply

Market Cap	5.35M
Revenue (ttm)	0.00
Net Income (ttm)	-27.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	619,700
Avg Vol	248,682
Day's Range	N/A - N/A
Shares Out	2.20M
Stochastic %K	9%
Beta	0.27
Analysts	Strong Sell
Price Target	$51.67